Discuva Ltd

Discovery and Development of Novel #Antibiotics. Tackling #AMR and #Superbugs

[Cambridge Business @cambridgebizuk]

Oxford raids Cambridge with £10m antibiotics firm deal: https://t.co/Ll41VLOrGX @DiscuvaLtd @Summitplc

[BSAC @BSACandJAC]

'A superbug is spreading through Irish hospitals at a rate of at least one new case a day, according to figures from an HSE emergency taskforce set up to monitor the issue' #AMR https://t.co/Aj4NP9IgtX

[Summit Therapeutics @SMMT_TX]

Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd.: https://t.co/VN1wDxAuH8

[Discuva Ltd @DiscuvaLtd]

New Year and good news, @DiscuvaLtd has been acquired by @Summitplc :
https://t.co/5FCFeQEudt

[Discuva Ltd @DiscuvaLtd]

@DiscuvaLtd part of the @AMRAlliance https://t.co/J9bJT3cvuY

[AMR IndustryAlliance @AMRAlliance]

Explore how we bring together Biotech, Generics, Diagnostics and R&D Pharma to #StopSuperbugs on our new website: https://t.co/3QobQzgLR3 #AMR

[Kevin Outterson @koutterson]

Our work on the WHO Priority Bacterial Pathogens List, published today in @TheLancetInfDis https://t.co/QcYBS8rpuw congratulations to @EveTacconelli and @WHO for their leadership on this project

[Discuva Ltd @DiscuvaLtd]

How European Union; One Health program plans to tackle Anti-microbial resistance? https://t.co/ZtukLb1Fgw

[World Health Organization (WHO) @WHO]

February 2017: WHO published a list of antibiotic-resistant priority pathogens to promote research and development of new #antibiotics https://t.co/iXvDutf2So #AntibioticResistance

[Business Weekly @businessweekly]

The @sangerinstitute is sequencing 25 new genomes of UK species including the floundering Red Squirrel, Water Vole, Turtle Dove and Northern February Red Stonefly. Read about the project in the digital edition of #BusinessWeekly https://t.co/9QDnT43Ipn

[Discuva Ltd @DiscuvaLtd]

“We are losing the battle to control #gonorrhoea” https://t.co/z4Fg7gd8Oj

[SIDP @SIDPharm]

Whoa. 🔬🔬🔬FDA launches new website and process for susceptibility testing interpretive criteria. FDA will update the information at least every six months. See the new website here @US_FDA: https://t.co/S3w7er5X7r

[BioIndustry Association (BIA) @BIA_UK]

Check out our latest blog 'Brexit and Trade – Implications for the Life Sciences Sector' by our Policy and Public Affairs Executive @johnsson_eric https://t.co/y0gXcGVuu5

[Discuva Ltd @DiscuvaLtd]

Inside CARB-X: can this new model for research fix a broken #antibiotics market? @CARB_X https://t.co/DNQhsGzbfM via @Pharmaceutical Technology

[Discuva Ltd @DiscuvaLtd]

Laboratories could face post-Brexit staffing crisis https://t.co/oYmnzuJ4Tb via @FT

[Discuva Ltd @DiscuvaLtd]

Life expectancy has dropped because of antibiotic resistance, says ONS https://t.co/n6q71efpCJ via @telegraphnews

[Bruce Booth @LifeSciVC]

In Search Of Novelty: 2017’s New FDA Drug Approvals. Fewer first-in-class mechanisms in this year's cohort of approvals. https://t.co/Q1bfTI1FMR

[Adam P Roberts 💙 @GCAGATGCAATG]

The Search for ‘Evolution-Proof’ Antibiotics: Trends in Microbiology https://t.co/AdhUt2vdbm

[Richard James @RichardJames39]

Given the need for new antibiotics to counter AMR this is a sobering analysis of the future of Pharma https://t.co/LCst6DMiji

[Discuva Ltd @DiscuvaLtd]

Study confirms, clarifies pathways in 2008 #superbug outbreak https://t.co/erL2QLlA2g

[Discuva Ltd @DiscuvaLtd]

Warning over ‘handful’ of scientists researching new #antibiotics https://t.co/KF2RotQB3g via @pharmaphorum